Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

APEL Appoints Senior Director

Published: Thursday, August 16, 2012
Last Updated: Thursday, August 16, 2012
Bookmark and Share
Appointment of Dr Susan Wood as Senior Director, Market Access.

Astellas Pharma Europe Ltd. (APEL) has appointed Dr Susan Wood as Senior Director, Market Access for Astellas Pharma Europe Ltd (APEL).

Formerly Senior Brand Director of APEL’s Pain Management franchise, she will now drive the Company’s market access activities with the aim of establishing its leadership in an area of ever increasing importance, in the face of current economic challenges.

She will report directly to Kay Drake, Vice President Marketing, Astellas Pharma Europe Ltd.

Welcoming Susan Wood to her new role, Ken Jones, President and CEO, Astellas Pharma Europe Ltd, said: “Astellas has proved time and again in recent years that it remains entirely possible to introduce effective new medicines that deliver value for payers - and that health services across Europe are willing to fund. Sue will be working closely with our Affiliates to drive the market access strategy across the Astellas Europe organization in our key therapeutic areas, focusing on developing evidence-based models from the early stages of R&D until the mature stages of the product lifecycle.”

Over the past three years, Susan Wood led the launch of QUTENZA™, an innovative treatment for peripheral neuropathic pain.

The successful introduction of QUTENZA has confirmed the value of integrating market access expertise at an early stage of strategic planning, and has also profiled Dr Wood’s abilities as a leader.

Commenting on her appointment, Susan Wood said: “Astellas Pharma Europe has recently launched its Oncology franchise, we are expecting some 11 products to be in launch or early-growth phase in the next three years. We are growing fast in Anti-Infectives, with the recently launched anti-infective DIFICLIR™, the first new treatment in 50 years for clostridium difficile (C.diff), and we continue to affirm our category leadership in Transplantation and Urology. I am very much looking forward to the challenge of supporting the company to achieve its strategic objectives.”

Susan Wood joined Astellas Pharma Europe Ltd in 2008 and has over 13 years’ experience in international pharmaceutical marketing, with a particular focus on launch strategies.

She previously held roles with Hoffmann-La Roche in Basel, Biogen in Paris and Sanofi Pasteur in Lyon. Before entering the pharmaceutical industry, she worked in clinical research.

Her academic background lies in neuroscience, with studies at both Oxford University and Harvard Medical School, and she has a PhD in Biochemistry, specializing in general anaesthesia.

Before entering the pharmaceutical industry she was also assistant editor of an international neuroscience journal.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!